Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Prodrugs

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood proteomics of paediatric bronchiolitis obliterans syndrome after haematopoietic cell transplant.

ERJ open research·2026

Same author

A lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis.

JCI insight·2026

Same author

Esomeprazole inhibits proliferation of scleroderma fibroblasts via cell cycle regulation.

Frontiers in pharmacology·2026

Same author

PLK1 inhibition by volasertib suppresses key transcriptional regulators underlying fibroblast activation and pulmonary fibrosis.

American journal of physiology. Lung cellular and molecular physiology·2026

Same author

Contribution of leukocyte telomere length to cardiovascular disease onset from genome-wide cross-trait analysis.

Nature communications·2025

Same author

From Gene Networks to Therapeutics: A Causal Inference and Deep Learning Approach for Drug Discovery.

Pharmaceuticals (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Drug repositioning for orphan diseases.

Divya Sardana¹, Cheng Zhu, Minlu Zhang

¹Department of Computer Science, University of Cincinnati, OH, USA.

Briefings in Bioinformatics

|April 21, 2011

Summary

Discovering new orphan disease therapeutics is challenging. Drug repositioning offers an efficient strategy by finding new uses for existing drugs, overcoming development hurdles.

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Related Experiment Videos

Last Updated: Jun 2, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Area of Science:

Drug discovery and development
Rare diseases
Pharmacology

Background:

Approximately 6000 rare diseases exist, with only 5% of interest to the biopharmaceutical industry due to low prevalence and commercial potential.
Traditional drug development is complex, costly, and has low success rates, exacerbating the scarcity of treatments for orphan diseases.
Existing drug repositioning successes are often serendipitous, highlighting a need for systematic approaches.

Purpose of the Study:

To review challenges in rational drug repositioning for orphan diseases.
To explore current methodologies for overcoming pharmacological and computational hurdles in drug repositioning.
To facilitate the translation of discoveries into effective orphan disease therapeutics.

Main Methods:

Review of existing literature on drug repositioning strategies for rare diseases.
Analysis of pharmacological and computational challenges in identifying novel drug-disease connections.
Discussion of methodologies for systematic identification of drug repurposing opportunities.

Main Results:

Drug repositioning presents a viable, efficient strategy to accelerate the development of therapeutics for rare diseases.
Significant pharmacological and computational challenges impede systematic drug repositioning.
Current information overload and intricate mechanisms obscure potential drug-disease links.

Conclusions:

Systematic and rational drug repositioning is crucial for addressing the unmet needs in orphan disease treatment.
Overcoming data complexity and understanding intricate mechanisms are key to successful drug repurposing.
This review highlights the importance of innovative methodologies to translate scientific discoveries into orphan disease therapies.